HBM1007, A Fully Human CD73 Antibody With Allosteric Inhibition & Strong Internalization Mediated Target Downregulation For Cancer Therapy

Time: 4:15 pm
day: Day Two


• Highlighting HMB1007 binds to a unique epitope of CD73 and shows high binding affinity to human and Cyno CD73

• Understanding HBM1007 demonstrates irreversible CD73 enzymatic blocking activity and induces CD73 endocytosis and degradation

• Divulging that HBM1007 achieves synergistic anti-tumor efficacy with anti-PD-1 or anti-CTLA-4 Abs

• HBM1007 shows good safety and developability profile